Position in NGNE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$186,561
+$66,972 QoQ
Shares Held
5,932
0.0% QoQ
Ownership
0.030%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#71
of 112 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MetLife Investment Management, LLC holds $430,307,229 across 249 Biotechnology names. NGNE ranks #194 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
402,605 | $31,511,893 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
90,543 | $30,312,890 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
58,072 | $28,846,104 | |
| 4 | FTRE |
Fortrea Holdings Inc.
|
1,362,169 | $23,701,740 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
89,662 | $21,946,567 | |
| 6 | IMNM |
Immunome Inc.
|
859,076 | $18,203,820 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,880 | $14,266,595 | |
| 8 | CYTK |
Cytokinetics Inc
|
140,046 | $11,930,518 |
All Filings in NGNE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $186,561 | 5,932 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $119,589 | 5,932 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $122,199 | 5,932 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $102,801 | 5,932 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $88,683 | 5,932 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $70,892 | 6,054 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $138,394 | 6,054 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $254,025 | 6,054 | Shares | Defined | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||